IP Library Granted Patent US 9,468,671
Granted Patent B2
US 9,468,671 · App. 14/317,106 · Granted Oct 18, 2016

Compositions and methods for promoting neuronal outgrowth

Inventors: Elliott A. Gruskin (Malvern, PA); Jennifer F. Iaci (Boonton, NJ); Andrea M. Vecchione (Mount Vernon, NY); Sarah J. Kasperbauer (Cortlandt Manor, NY); Gargi Roy (Boyds, MD)
Assignee: Acorda Therapeutics, Inc.
A61K38/51C12N9/88C12Y402/02005C12Y402/02019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,468,671
App. No.
14/317,106
Granted
Oct 18, 2016
Kind
B2
Abstract

Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.

Claims (9)

1. A method of treating a subject having a glial scar due to an injury to the central nervous system comprising administering an effective amount of chondroitinase AC, chondroitinase B, or a mixture thereof to the subject.

2. The method of claim 1 , wherein administering is selected from topical, local and systemic.

3. The method of claim 2 , wherein local administration uses a mode selected from a catheter, a syringe, and direct application to the injury.

4. The method of claim 1 , wherein chondroitinase AC is administered.

5. The method of claim 4 , wherein the chondroitinase AC is selected from the group consisting of chondroitinase AC, chondroitinase AC II and chondroitinase AC III.

6. The method of claim 1 , wherein chondroitinase B is administered.

7. The method of claim 1 , wherein a combination of a chondroitinase AC and chondroitinase B is administered.

8. The method of claim 1 , wherein the chondroitinase AC, chondroitinase B or a mixture thereof is administered as a composition comprising a pharmaceutically acceptable carrier.

9. The method of claim 1 , wherein the effective amount is administered in multiple doses.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2014
From: GRUSKIN, ELLIOTT A.; IACI, JENNIFER F.; VECCHIONE, ANDREA; KASPERBAUER, SARAH; ROY, GARGI
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 033932/0653 →
Continuity (4)
Continuation 13451968 · Apr 20, 2012
Continuation 10513573
Provisional Application 60377669 · May 4, 2002
Related Publication 20150023942A1 · Jan 22, 2015